Home/Pipeline/TLX591

TLX591

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Phase 3Active (ProstACT SELECT)NCT04876651

Key Facts

Indication

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Phase

Phase 3

Status

Active (ProstACT SELECT)

Company

Telix Pharmaceuticals Limited

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals is a global leader in radiopharmaceuticals, focusing on theranostics—a combined diagnostic and therapeutic approach for cancer. The company has achieved commercial success with its FDA-approved prostate cancer imaging agent, Illuccix®, and is advancing a deep clinical pipeline targeting renal, brain, and other cancers. With a vertically integrated platform spanning discovery to commercialization, Telix is strategically positioned to capture significant value in the high-growth precision oncology market.

View full company profile

Therapeutic Areas

Oncology Urologic Cancer Renal Cancer Brain Cancer

Other Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drugs

Drug	Company	Phase	Status
Tomivosertib	eFFECTOR Therapeutics	Phase 2	Terminated
Gedatolisib + Darolutamide	Celcuity	Phase 1b/3	Active
SNP-101 (estimated)	SmartNuclide Biopharma	Phase 1	Active
AB001 (²¹²Pb-NG001)	ARTBIO	Phase 1/2	Active - First patient dosed in ARTISAN trial (Jan 2026)
AB-3028	Arsenal Biosciences	IND-Enabling	Active
PRO CAR-201A	PromiCell	Phase 1	Active
PRO CAR-202	PromiCell	Preclinical	Active
FG-3246	Kyntra Bio	Phase 2	Active
PROVENGE (sipuleucel-T)	Dendreon	Approved	Active
RP12146	Rhizen Pharmaceuticals	Phase 1b	Active
Monoclonal Antibody (undisclosed)	MetaCurUm Biotech	Preclinical	Active
ModraDoc006/r	Modra Pharmaceuticals	Phase 2b	Active